Rare diseases
Investigational molecules
Locations
Back to Germany34 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer
GermanyStudy of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment
GermanyStudy Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer
GermanyStudy of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
GermanyStudy on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy
GermanyStudy on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy
GermanyStudy on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal
GermanyStudy on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer
GermanyStudy on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
GermanyStudy of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer
GermanyThe busiest research cities in the country
What the registry says about research in the country
Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.
Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.
Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.
Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.
Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.
Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
